CAMBRIDGE, Mass.--(BUSINESS WIRE)--Theracrine, Inc., the first biopharmaceutical company focused on the discovery and development of novel therapeutics to treat cancer spread, today announced the publication of research from the lab of scientific founder Joan Massagué, Ph.D. in Cancer Cell that elucidates the fundamental nature of cancer spread as well as the role of tumor-stromal interactions. The research specifically demonstrates the central role of VCAM-1 and VLA-4 in the survival and growth of metastatic breast cancer cells. These new findings provide for a novel avenue by which the biology of cancer spread can be interrupted to reduce ongoing survival signaling and thereby improve cancer patient outcomes.
